The Phase 1b trial of VLS-01 investigates the pharmacokinetics, pharmacodynamics, safety and tolerability of atai’s proprietary, optimized oral transmucosal formulation…
Ethics and regulatory approvals finalized for world-first take-home use of a psychedelic medicine MB22001 in placebo-controlled trial in depressed patients…
VIRGINIA BEACH, VA / ACCESSWIRE / February 29, 2024 / Inspire Veterinary Partners, Inc. (NASDAQ:IVP) ("Inspire" or the "Company"), an…
AWRS Actively Pursuing In-Network Commercial Insurance CoverageBRENTWOOD, TN / ACCESSWIRE / February 27, 2024 / Another Way Recovery Services Inc.,…
BELLEVUE, WA / ACCESSWIRE / February 27, 2024 / THIRA Health, a mental health treatment center in Bellevue, Washington, is…
NEW YORK, Feb. 26, 2024 /PRNewswire/ -- Anise Health, a culturally-responsive digital mental health platform, is expanding its individual and…
U.S. employers frustrated by soaring costs and fragmented solutions share data on specific cancer types and care driving spend, seek…
90% of K-12 Teachers Are Experiencing Burnout, Higher Than Any Other Industry FORT WORTH, Texas, Feb. 26, 2024 /PRNewswire/ --…
Houston, Texas--(Newsfile Corp. - February 26, 2024) - Cannabis Bioscience International Holdings (OTC Pink: CBIH) is excited to announce that…
MindBio demonstrates safe, effective take home use of MB22001 in Depressed patients over an 8-week, world first take-home trialRapid, robust,…